labetalol has been researched along with Chronic Disease in 18 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This double-blind, controlled, crossover study compared the effects on blood pressure control, glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) of labetalol, methyldopa and placebo in patients with chronic renal disease and hypertension." | 9.07 | The short term effects of oral labetalol in patients with chronic renal disease and hypertension. ( Catto, GR; Edward, N; Gemmell, HG; Innes, A; Smith, FW, 1992) |
| "In 14 patients with essential hypertension, the influence of the alpha- and beta-adrenoceptor blocking drug labetalol on blood pressure, heart rate, plasma renin, plasma noradrenaline and pressor effect of exogenous noradrenaline was investigated during long-term treatment." | 7.66 | Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension. ( Distler, A; Lüth, JB; Neurohr, W; Philipp, T; Zschiedrich, H, 1983) |
| "This was a nested cohort study of women with chronic hypertension and a singleton pregnancy recruited to the PANDA (Pregnancy And chronic hypertension: NifeDipine vs lAbetalol as antihypertensive treatment) study at one of three UK maternity units." | 5.30 | Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study. ( Chappell, LC; Cruickshank, JK; Khalil, A; Mills, C; Myers, JE; Nelson-Piercy, C; Seed, PT; Watt-Coote, I; Webster, LM, 2019) |
| "This double-blind, controlled, crossover study compared the effects on blood pressure control, glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) of labetalol, methyldopa and placebo in patients with chronic renal disease and hypertension." | 5.07 | The short term effects of oral labetalol in patients with chronic renal disease and hypertension. ( Catto, GR; Edward, N; Gemmell, HG; Innes, A; Smith, FW, 1992) |
| "This is the first reported large clinical trial of the antianginal and acute ischemic effectiveness and safety of dilevalol (the R, R-isomer of labetalol) in patients with chronic stable angina pectoris." | 5.06 | The efficacy and safety of dilevalol in patients with chronic stable angina pectoris. ( Bennett, WT; Bittar, N; Glasser, SP; Kinhal, V; Koehn, DK, 1989) |
| " The American College of Obstetricians and Gynecologists recommends that acute-onset, severe hypertension be treated with first line-therapy (intravenous labetalol, intravenous hydralazine or oral nifedipine) within 60 minutes to reduce risk of maternal morbidity and death." | 3.96 | Identification of factors associated with delayed treatment of obstetric hypertensive emergencies. ( Akerman, MB; Elsayad, A; Halpern, TA; Heiselman, CJ; Heo, HJ; Kantorowska, A; Muscat, JC; Sicuranza, GB; Vintzileos, AM, 2020) |
| "Labetalol is commonly used for control of hypertension in pregnancy." | 3.77 | False-positive amphetamine toxicology screen results in three pregnant women using labetalol. ( Wu, D; Yee, LM, 2011) |
| "In 14 patients with essential hypertension, the influence of the alpha- and beta-adrenoceptor blocking drug labetalol on blood pressure, heart rate, plasma renin, plasma noradrenaline and pressor effect of exogenous noradrenaline was investigated during long-term treatment." | 3.66 | Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension. ( Distler, A; Lüth, JB; Neurohr, W; Philipp, T; Zschiedrich, H, 1983) |
| " Thus the bioavailability of labetalol was increased in liver disease due to reduced first-pass metabolism." | 2.64 | Decreased first-pass metabolism of labetalol in chronic liver disease. ( Homeida, M; Jackson, L; Roberts, CJ, 1978) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "Women with chronic hypertension are at significant risk for maternal and fetal morbidity and mortality, yet it remains unclear whether antihypertensive treatment during pregnancy lowers these risks." | 2.55 | New Evidence in the Management of Chronic Hypertension in Pregnancy. ( August, P; Podymow, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (27.78) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Kantorowska, A | 1 |
| Heiselman, CJ | 1 |
| Halpern, TA | 1 |
| Akerman, MB | 1 |
| Elsayad, A | 1 |
| Muscat, JC | 1 |
| Sicuranza, GB | 1 |
| Vintzileos, AM | 1 |
| Heo, HJ | 1 |
| Miller, J | 1 |
| McNaughton, C | 1 |
| Joyce, K | 1 |
| Binz, S | 1 |
| Levy, P | 1 |
| Podymow, T | 1 |
| August, P | 1 |
| Webster, LM | 1 |
| Myers, JE | 2 |
| Nelson-Piercy, C | 1 |
| Mills, C | 1 |
| Watt-Coote, I | 1 |
| Khalil, A | 1 |
| Seed, PT | 1 |
| Cruickshank, JK | 1 |
| Chappell, LC | 1 |
| Shawkat, E | 1 |
| Mistry, H | 1 |
| Chmiel, C | 1 |
| Webster, L | 1 |
| Chappell, L | 1 |
| Johnstone, ED | 1 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Olson-Chen, C | 1 |
| Seligman, NS | 1 |
| Liu, X | 1 |
| Yang, le J | 1 |
| Fan, SJ | 1 |
| Jiang, H | 1 |
| Pan, F | 1 |
| Yee, LM | 1 |
| Wu, D | 1 |
| Zschiedrich, H | 1 |
| Neurohr, W | 1 |
| Lüth, JB | 1 |
| Philipp, T | 1 |
| Distler, A | 1 |
| Gulati, OP | 1 |
| Gulati, N | 1 |
| Palla, R | 1 |
| Bionda, A | 1 |
| Carmassi, F | 1 |
| Giusti, R | 1 |
| Marchitiello, M | 1 |
| Spierings, EL | 1 |
| Homeida, M | 1 |
| Jackson, L | 1 |
| Roberts, CJ | 1 |
| Innes, A | 1 |
| Gemmell, HG | 1 |
| Smith, FW | 1 |
| Edward, N | 1 |
| Catto, GR | 1 |
| Bowles, MJ | 1 |
| Smith, L | 1 |
| Glover, DR | 1 |
| Wong, CK | 1 |
| Lau, CP | 1 |
| Leung, WH | 1 |
| Cheng, CH | 1 |
| Glasser, SP | 1 |
| Bittar, N | 1 |
| Kinhal, V | 1 |
| Bennett, WT | 1 |
| Koehn, DK | 1 |
4 reviews available for labetalol and Chronic Disease
| Article | Year |
|---|---|
Hypertension Management in Emergency Departments.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2020 |
New Evidence in the Management of Chronic Hypertension in Pregnancy.
Topics: Algorithms; Antihypertensive Agents; Blood Pressure; Chronic Disease; Female; Humans; Hypertension; | 2017 |
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
Hypertensive Emergencies in Pregnancy.
Topics: Antihypertensive Agents; Cesarean Section; Chronic Disease; Congenital Abnormalities; Emergencies; E | 2016 |
6 trials available for labetalol and Chronic Disease
| Article | Year |
|---|---|
Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study.
Topics: Adult; Antihypertensive Agents; Birth Weight; Black People; Blood Pressure; Chronic Disease; Cohort | 2019 |
Decreased first-pass metabolism of labetalol in chronic liver disease.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Chronic Disease; Ethanolamines; Female; | 1978 |
The short term effects of oral labetalol in patients with chronic renal disease and hypertension.
Topics: Administration, Oral; Adult; Blood Pressure; Chronic Disease; Double-Blind Method; Female; Glomerula | 1992 |
Randomised, double-blind, three-way cross-over study of dilevalol 200 and 400 mg and atenolol 100 mg once-daily in patients with chronic stable angina pectoris.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Angina Pectoris; Atenolol; Blood Pressure; | 1990 |
Usefulness of labetalol in chronic atrial fibrillation.
Topics: Atrial Fibrillation; Chronic Disease; Digoxin; Double-Blind Method; Drug Therapy, Combination; Elect | 1990 |
The efficacy and safety of dilevalol in patients with chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind | 1989 |
8 other studies available for labetalol and Chronic Disease
| Article | Year |
|---|---|
Identification of factors associated with delayed treatment of obstetric hypertensive emergencies.
Topics: Administration, Intravenous; Administration, Oral; Adult; After-Hours Care; Antihypertensive Agents; | 2020 |
The effect of labetalol and nifedipine MR on blood pressure in women with chronic hypertension in pregnancy.
Topics: Adrenergic Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Chronic D | 2018 |
Swimming exercise effects on the expression of HSP70 and iNOS in hippocampus and prefrontal cortex in combined stress.
Topics: Acute Disease; Adrenergic Antagonists; Animals; Chronic Disease; Corticosterone; Hippocampus; HSP70 | 2010 |
False-positive amphetamine toxicology screen results in three pregnant women using labetalol.
Topics: Adult; Amphetamine; Antihypertensive Agents; Cesarean Section; Chronic Disease; Cocaine; Cross React | 2011 |
Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension.
Topics: Adult; Blood Pressure; Chronic Disease; Dose-Response Relationship, Drug; Drug Interactions; Ethanol | 1983 |
Effects of labetalol in chronic two-kidney Goldblatt hypertension (2-KGH) in rats.
Topics: Animals; Blood Pressure; Chronic Disease; Ethanolamines; Heart; Heart Rate; Hypertension, Renal; Lab | 1980 |
[Effect of treatment with labetalol on renal function in arterial hypertension secondary to parenchymal nephropathy and in essential arterial hypertension].
Topics: Adult; Chronic Disease; Ethanolamines; Glomerulonephritis; Humans; Hypertension; Hypertension, Renal | 1980 |
Acute and chronic hypertensive headache and hypertensive encephalopathy.
Topics: Acute Disease; Antidepressive Agents; Antihypertensive Agents; Anxiety; Arterioles; Cerebral Arterie | 2002 |